Indeed, immune checkpoint inhibitors have arisen as an option to treat cancer from the parallel drawn with the exhausted phenotype of T-cells and the high expression of inhibitory receptors, such as Programmed cell death 1 (PD-1), in chronic infectious diseases [6,7]. This evidence concerns the gene PDCD1 and cancer.